Loading organizations...
§ Private Profile · San Diego, CA, USA
Biotechnology developing small molecule precision medicines for cancer & autoimmune diseases, targeting tumor resistance.
BlossomHill Therapeutics is a clinical-stage biotechnology company that designs small molecule precision medicines for the treatment of complex cancer and autoimmune diseases. The organization focuses on developing innovative drug candidates that overcome tumor resistance, specifically targeting blood and lung cancers to compete with existing therapies like AstraZeneca’s Tagrisso. To date, the enterprise has raised a total of $173 million in venture capital funding to support the advancement of its pipeline of novel therapeutic candidates. This financial backing includes a $100 million financing round completed in February 2024, which was supported by prominent institutional investors such as Colt Ventures, Cormorant Asset Management, and OrbiMed. The company is currently utilizing this recent capital injection to prepare its primary oncology medicines for their initial human clinical studies. BlossomHill Therapeutics was originally founded by scientific researchers J. Jean Cui and Peter Li.
BlossomHill Therapeutics has raised $255.0M across 3 funding rounds.
BlossomHill Therapeutics has raised $255.0M in total across 3 funding rounds.
BlossomHill Therapeutics has raised $255.0M in total across 3 funding rounds.
BlossomHill Therapeutics's investors include Brahma Capital, Vish Sridharan, Cormorant Asset Management, OrbiMed, Plaisance Capital Management, Vivo Capital, Sundeep Agrawal, General Catalyst, Sofinnova Investments, Bihua Chen, H&D Asset Management, Hercules BioVentures Partners.
BlossomHill Therapeutics has raised $255.0M across 3 funding rounds. Most recently, it raised $84.0M Series B Extension in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2025 | $84M Series B Plus | Brahma Capital, Vish Sridharan | Cormorant Asset Management, OrbiMed, Plaisance Capital Management, Vivo Capital | Announced |
| Jan 1, 2024 | $100M Series B | Sundeep Agrawal | General Catalyst, OrbiMed, Sofinnova Investments, Bihua Chen, H&D Asset Management, Hercules Bioventures Partners, Plaisance Capital Management, Timothy Stubbs | Announced |
| Mar 1, 2021 | $71M Series A | Bihua Chen | General Catalyst, OrbiMed, Sofinnova Investments, George J. LEE, Vivo Capital | Announced |
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company designing and developing next-generation small-molecule therapies for cancer and autoimmune diseases.[1][2] Founded by J. Jean Cui, Ph.D., the company focuses on precision medicines that target oncogenic drivers and resistance mechanisms, with lead programs including BH-30643 (a first-in-class macrocyclic OMNI-EGFR inhibitor for EGFR/HER2-mutated NSCLC) and BH-30236 (a macrocyclic CLK inhibitor for R/R AML or HR-MDS).[2][4] It serves patients with difficult-to-treat cancers and autoimmune conditions, addressing unmet needs like treatment resistance through intelligently designed drugs built from the ground up.[1][2] The company has raised $257 million total, including an $84 million Series B extension in 2025 led by Janus Henderson Investors, accelerating its pipeline.[2]
BlossomHill Therapeutics was founded in 2020 in San Diego, California, by J. Jean Cui, Ph.D., a prolific drug designer with a track record of three FDA-approved cancer drugs: repotrectinib (AUGTYRO®), crizotinib (XALKORI®), and lorlatinib (LORBRENA®).[1][2][3] Cui, inspired by the need to transcend incremental advances in precision medicine, combined her scientific expertise with creative thinking to build novel therapeutic candidates.[1] Y. Peter Li serves as co-founder, with prior collaboration on Turning Point Therapeutics, which Cui and Li founded and Bristol Myers Squibb acquired in 2022.[1][3] Early momentum came from assembling a world-class pipeline and securing funding from top investors like OrbiMed and Vivo Capital.[2]
BlossomHill rides the wave of precision oncology and targeted therapies, capitalizing on advances in mutant-selective inhibitors amid rising NSCLC and AML incidences.[2][4] Timing aligns with post-2022 oncology M&A trends, building on Cui's Turning Point success acquired by Bristol Myers Squibb, amid a biotech funding rebound in 2025.[1][2] Market forces like demand for resistance-breaking drugs favor its macrocyclic designs, addressing limitations in existing EGFR/CLK therapies.[1][2] It influences the ecosystem by validating small-molecule innovation from serial entrepreneurs, attracting capital to San Diego's biotech hub and advancing clinical trials for hard-to-treat cancers.[4]
BlossomHill is poised for milestone readouts from BH-30643 and BH-30236 trials, potentially driving partnerships or acquisition interest given its $257M war chest and founder's pedigree.[2][4] Trends like AI-augmented drug design and immuno-oncology combos will shape its path, expanding its autoimmune programs amid a push for multi-modal therapies.[1] Influence may grow through FDA nods or buyouts, solidifying its role in leapfrogging precision medicine—echoing its mission to create medical masterpieces that extend patient lifespans.[1]